|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 3
|
Positive data could expand use of Novartis’ gene therapy for SMA
|
|
Dec 31
|
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
|
|
Dec 31
|
Here's Why Novartis (NVS) is a Strong Growth Stock
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|
|
Oct 1
|
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
|
|
Sep 30
|
Top Research Reports for Apple, Tesla & T-Mobile US
|
|
Sep 30
|
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
|
|
Sep 27
|
Volkswagen, Novartis could surprise in Q3 earnings season, UBS analysts warn
|
|
Sep 25
|
Generate:Biomedicines and Novartis link on protein therapeutics development
|
|
Jul 25
|
Dren Bio and Novartis link on bispecific antibodies for cancer
|
|
Jul 24
|
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
|
|
Jul 24
|
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
|
|
Jun 20
|
Here's Why Novartis (NVS) is a Strong Momentum Stock
|
|
Jun 19
|
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
|
Jun 17
|
EHA 2024: Novartis Scemblix takes on all TKIs in head-to-head CML trial
|
|
May 3
|
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
|
|
May 3
|
Why selling to Novartis made sense for Mariana
|